Lexicon Pharmaceuticals secures $100M loan facility from Hercules Capital to boost financial flexibility.

Lexicon Pharmaceuticals has entered a $100 million loan facility agreement with Hercules Capital, with $55 million funded immediately to repay an existing loan. This non-dilutive financing offers Lexicon extended interest-only periods and flexibility to support upcoming regulatory and commercial milestones, especially for its late-stage cardiometabolic drug programs. The loan includes options for additional draws based on milestone achievements and carries a floating interest rate with a maturity date in 2030. This move strengthens Lexicon's balance sheet and supports its long-term growth strategy in biotech innovation.